Journal: Current Protocols in Stem Cell Biology

Article Title: Generation of Complete Multi−Cell Type Lung Organoids From Human Embryonic and Patient‐Specific Induced Pluripotent Stem Cells for Infectious Disease Modeling and Therapeutics Validation

doi: 10.1002/cpsc.118

Figure Lengend Snippet: Antibodies Used in FACS and Immunofluorescence

Article Snippet: p63 , Boster , PB9152 , 1:250.

Techniques:

Journal: Translational Vision Science & Technology

Article Title: Universal Corneal Epithelial-Like Cells Derived from Human Embryonic Stem Cells for Cellularization of a Corneal Scaffold

doi: 10.1167/tvst.7.5.23

Figure Lengend Snippet: Generation, characterization, and differentiation efficiency of hESC-derived CEC. CEC were derived from H9 hESC, and three biological replicates were set up for each sample, and each experiment was repeated at least twice (the same hereafter unless stated otherwise). (A) A schematic showing the protocol for hESC differentiation into CEC in E6 with the cells split at day 40. (B) Morphology of the differentiated cells at days 10 and 40. Scale bar: 400 μm (a, b, c) and 100 μm (a', b', c'). (C) Flow cytometry analyses for the pluripotency marker NANOG, the corneal developmental markers PAX6, TP63, and KRT15, and the mature CEC markers KRT3 and KRT12 in hESC that differentiated in E6 for the designated times. (D) Immunostaining for TP63, PAX6, and KRT15 at day 45 of differentiation, and KRT3 and KRT12 at day 75. Scale bar: 50 μm for all images. (E) Real-time PCR analysis for expression of marker genes for pluripotency, CEC progenitors, and mature CEC, and transparency-associated genes during hESC differentiation to CEC for 8 weeks.

Article Snippet: The fixed cells were incubated in 0.1% Triton X-100 solution for 10 minutes, blocked in 5% bovine serum albumin (BSA) for 1 hour, and incubated with antibodies against NANOG (Cell Signaling Technologies), PAX6 (Invitrogen), TP63 (Boster, Pleasanton, CA) or KRT15 (Santa Cruz Biotechnology, Inc., Dallas, TX), HLA-A/B/C (ebioscience, San Diego, CA), B2M (Sigma-Aldrich Corp., St. Louis, MO) at the dilution ratio of 1:100 overnight in a cold room.

Techniques: Derivative Assay, Flow Cytometry, Marker, Immunostaining, Real-time Polymerase Chain Reaction, Expressing

Journal: BMC Gastroenterology

Article Title: Characteristics, clinical outcomes and patient-reported outcomes of patients with ulcerative colitis receiving tofacitinib: a real-world survey in the United States and five European countries

doi: 10.1186/s12876-023-02640-7

Figure Lengend Snippet: Selection pathway of patients with UC in the analysis groups. Legend: Patients were abstracted from the patient data collected in Adelphi Ulcerative Colitis Disease Specific Programme™ (DSP) survey

Article Snippet: Therefore, to support the robust tofacitinib clinical trial data, we present data from the well-established Adelphi Ulcerative Colitis Disease Specific Programme™ (DSP) [ ].

Techniques: Selection